Ive noticed a new trend the pump and dump promoters have started to try to gain your trust back after burning you so many times on their crappy plays. Its their new Mind The Gap theory. The very title of it gives away that they are trying to manipulate the stock and make it easier for you to get in so that ultimately
they and their insiders can get out. Ive watched several such plays this week and they have pretty much fizzled immediately after the announcement that they are in.
This ploy they are engaging in is designed to get you to jump in quick on your emotions, and remember we NEVER want to trade on emotion. By engaging in this practice they believe they can create buying pressure and in turn move the stock upward. What is happening though is people are keen to their ways and are bailing before it ever gets started.
The new excuse they use is the stock had good volume but was having technical issues. HELLOOOOO
even stocks that plummet have alot of volume.... DUH. They continue to think you are stupid and will follow them and their "Concern" for your profit making when in reality they are only concerned with their own paycheck and the ratios they have illegally promised the people who have hired them to promote the stock.
Dont fall prey to these idiots. Look at their last play and see how it did. Those of us in the trading world know that your only as good as your last promotion so GET OFF OF IT pumpers !!!
The opinions expressed are mine and mine alone. I am Not a licensed Stock Broker or Financial advisor.
Never invest money you cant afford to entirely lose.
Friday, January 27, 2012
Wednesday, January 25, 2012
Diversified Stock Investing
In this day and age of trying to plan for the future while making a quick buck it is important to diversify our investing into several different sectors so as to give ourselves the best chance for long term growth. Not all sectors always grow at the same times. Sometimes its banking and finance, sometimes its technology or retail, and other times its manufacturing or metals. I believe its best to dedicate our money in several different areas and do the due diligence necessary to pick the right stocks.
Penny and Sub-Penny stocks should never get more than 20% of my total money I have to invest. That is like my play money if I must play with fire. I like a breakdown of 30% in banking and finance, 30% in technology or retail and 40% in bio pharmaceutical stocks.
Banking and Finance:
After the 2008 crash, the government stepped in and started unprecedented banking and finance reform.
It is my opinion that based on those reforms given a similar crash, the federal government will not ever let a large major bank go bankrupt. So, my money would be in 2 larger banks or finance companies and I would do my due diligence and look at the long term growth projections in those banks. I would then sit on them through the highs and lows and get my continued growth in that sector. I am not going to throw out tickers or recommendations as I want you to do your homework and pick your own as that is what empowers you through your own hard work and dedication.
Technology:
Have you ever bought a piece of technology like a phone or television that is the best piece ever and then six months later see the new and improved model that makes yours like a dinosaur? I sure have.
The technology sector is always developing new and improved ideas of how to make our lives easier and lazier and in my opinion is a solid investment area if you are in the right companies. Again, do your due diligence and pick companies that you can relate to their products through your own personal everyday use. Then, pick a couple of companies and invest another 30% of the total money you have available between those couple of companies.
Bio-Pharmaceutical Companies:
This is personally my favorite sector. I like it because people are always sick and we are always looking for ways to cure and alleviate ailments and diseases so I see it as having unlimited growth potentials. Bio-Pharmaceutical companies are rich in information about the results of new tests and drugs therefore allowing me to position myself at the right times to maximize my gains and minimize my losses. Investing in these companies though does take a little more ongoing monitoring so I would only get in them if I have the time to watch them closely. Again, 40% of my available money to invest would be put in these stocks.
Happy trading and Good luck investing in YOUR future.
The opinions expressed in this blog are mine and mine only and are not intended to be recommendations. As always never invest money you cannot afford to lose and do your own Due Diligence.
Penny and Sub-Penny stocks should never get more than 20% of my total money I have to invest. That is like my play money if I must play with fire. I like a breakdown of 30% in banking and finance, 30% in technology or retail and 40% in bio pharmaceutical stocks.
Banking and Finance:
After the 2008 crash, the government stepped in and started unprecedented banking and finance reform.
It is my opinion that based on those reforms given a similar crash, the federal government will not ever let a large major bank go bankrupt. So, my money would be in 2 larger banks or finance companies and I would do my due diligence and look at the long term growth projections in those banks. I would then sit on them through the highs and lows and get my continued growth in that sector. I am not going to throw out tickers or recommendations as I want you to do your homework and pick your own as that is what empowers you through your own hard work and dedication.
Technology:
Have you ever bought a piece of technology like a phone or television that is the best piece ever and then six months later see the new and improved model that makes yours like a dinosaur? I sure have.
The technology sector is always developing new and improved ideas of how to make our lives easier and lazier and in my opinion is a solid investment area if you are in the right companies. Again, do your due diligence and pick companies that you can relate to their products through your own personal everyday use. Then, pick a couple of companies and invest another 30% of the total money you have available between those couple of companies.
Bio-Pharmaceutical Companies:
This is personally my favorite sector. I like it because people are always sick and we are always looking for ways to cure and alleviate ailments and diseases so I see it as having unlimited growth potentials. Bio-Pharmaceutical companies are rich in information about the results of new tests and drugs therefore allowing me to position myself at the right times to maximize my gains and minimize my losses. Investing in these companies though does take a little more ongoing monitoring so I would only get in them if I have the time to watch them closely. Again, 40% of my available money to invest would be put in these stocks.
Happy trading and Good luck investing in YOUR future.
The opinions expressed in this blog are mine and mine only and are not intended to be recommendations. As always never invest money you cannot afford to lose and do your own Due Diligence.
Tuesday, January 24, 2012
Keeping your emotions in check and your options open
Good Day all, I wanted to take a moment today to give you an example of keeping your emotions in check and your options open. Under normal circumstances most stocks that gap up or down at open fill that gap often during the first hour of trading. Trading solely on alerts or newsletters from promoters often lock you in during the volatile times and we risk getting wrapped up in the emotions we go through when we see our stock choice gapping up or down so quickly. For example yesterday MDCE gapped up 111% at the open after the promoter promoting it announced days prior that the ticker announcement would be after the opening bell to avoid such a gap. That open was at best fishy and a total trap.
7 minutes after the big ticker announcement the stock plummeted down 35% from its open and then 4 minutes later it was down another 53% and ended up closing up 35%. A huge trap for those less than savvy traders, as most seeing the initial gap up would think OMG I have to get on this train before it leaves the station and then would have lost their butts in this classic Gap and Trap farce. This stock never was even close to the 50 day moving avg, so I would have never gotten in this one.
This is why unless I have my position prior to open I never ever get in during that first hour as this stock never recovered to its high of the day (HOD) and if id tried to get in after open unless I was shorting the stock I would have lost my butt.
So keep your emotions in check and be patient. If you miss out on this one there is always the next one.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
7 minutes after the big ticker announcement the stock plummeted down 35% from its open and then 4 minutes later it was down another 53% and ended up closing up 35%. A huge trap for those less than savvy traders, as most seeing the initial gap up would think OMG I have to get on this train before it leaves the station and then would have lost their butts in this classic Gap and Trap farce. This stock never was even close to the 50 day moving avg, so I would have never gotten in this one.
This is why unless I have my position prior to open I never ever get in during that first hour as this stock never recovered to its high of the day (HOD) and if id tried to get in after open unless I was shorting the stock I would have lost my butt.
So keep your emotions in check and be patient. If you miss out on this one there is always the next one.
Monday, January 23, 2012
Positive due diligence
I decided I wanted to show you another good due diligence so I whipped up one on Wyndam Worldwide to so that you can see the kind of information we look for and what is a good presentation of due diligence. Enjoy!!
WYN Company Overview & Description
Wyndham Worldwide is one of the world's largest hospitality companies across six continents. We offer individual consumers and business customers a broad array of hospitality products and services as well as various accommodation alternatives and price ranges through our premier portfolio of world-renowned brands.
The Company operates in the following business segments:
*Lodging —franchises hotels in the upper upscale, upscale, upper midscale, midscale, economy and extended stay segments of the lodging industry and provides hotel management services for full-service hotels globally.
*Vacation Exchange and Rentals —provides vacation exchange services and products to owners of intervals of vacation ownership interests (“VOIs”) and markets vacation rental properties primarily on behalf of independent owners.
*Vacation Ownership —develops, markets and sells VOIs to individual consumers, provides consumer financing in connection with the sale of VOIs and provides property management services at resorts.
Wyndham Vacation Rentals, the world's largest professionally managed vacation rentals business, is part of Wyndham Exchange & Rentals and the Wyndham Worldwide family of brands (NYSE: WYN). Backed by the world's largest hospitality company, Wyndham Vacation Rentals provides access to more than 94,000 vacation rental properties in over 500 unique destinations worldwide. Specializing in the managed vacation rental segment, Wyndham works closely with property owners to ensure all rentals meet its standards for customer service, quality and comfort. With a diverse and celebrated collection of more than 25 rental brands including Canvas Holidays, Hoseasons, James Villa Holidays, Landal GreenParks(R), Novasol(R), ResortQuest(R) and The Resort Company, Wyndham Vacation Rentals delivers distinct vacation experiences, ranging from beachfront condos, private homes, villas, castles and houseboats, with many properties offering kitchens, washers and dryers, maid service, spa and fitness centers, and golf courses. For additional information visit our media center at http://www.wyndhamworldwide.comor http://www.wyndhamrentals.com. Wyndham Vacation Rentals also can be found on Facebook at http://www.facebook.com/WyndhamWorldwide
http://youtu.be/0O3w09UWrRs
Key Company Management
Stephen P. Holmes
Chairman and Chief Executive Officer
Stephen P. Holmes has served as the Chairman of our Board of Directors and as our Chief Executive Officer since our listing on the New York Stock Exchange in July 2006. Prior to the creation of Wyndham Worldwide, Mr. Holmes was Vice Chairman and Director of Cendant and CEO of it's Travel Content Division since December 1997. Mr. Holmes was Vice Chairman and director of HFS Incorporated, from June 1994 until December 1997. From July 1990 through September 1996, Mr. Holmes served as Executive Vice President, Treasurer and Chief Financial Officer of HFS. Prior to the formation of HFS, Mr. Holmes was a managing director of The Blackstone Group and began his career as a Certified Public Accountant with Deloitte.
Geoff Ballotti
President and Chief Executive Officer
Wyndham Exchange & Rentals
Geoff Ballotti has served as president and chief executive officer, Wyndham Exchange & Rentals, since March 2008. In this role, Ballotti oversees more than 8,000 associates working in 72 offices in 33 countries. As president and CEO, he manages Wyndham Vacation Rentals, a diverse and celebrated collection of more than 25 vacation rentals brands from around the world, and RCI, the global leader in vacation exchange with a network of more than 4,000 affiliated resorts around the world and more than 3.7 million members. Prior to joining Wyndham Worldwide, Ballotti was president of the North America division of Starwood Hotels and Resorts. Geoff also brings international and global experience to Wyndham Exchange & Rentals, having led operations for Starwood in Europe. He speaks both French and Italian.
Eric A. Danziger
President and Chief Executive Officer
Wyndham Hotel Group
Eric A. Danziger has served as President and Chief Executive Officer of Wyndham Hotel Group since December 2008. Mr. Danziger has more than 30 years of hotel industry experience, starting as a bellman at the Fairmont Hotel in San Francisco and growing into progressively senior roles in hotel operations, general management and regional operations. His most recent hospitality experience includes serving as President and Chief Operating Officer of Carlson Hotels Worldwide, President and CEO of Starwood Hotels and Resorts Worldwide, and President of Wyndham Hotels and Resorts. Prior to joining Wyndham Worldwide, Danziger was CEO of WhiteFence, an online one–stop comparison shopping and transaction site for home services, and before that, president and CEO of ZipRealty, a national, full–service real estate brokerage.
Franz S. Hanning
President and Chief Executive Officer
Wyndham Vacation Ownership
Franz S. Hanning has served as President and Chief Executive Officer, Wyndham Vacation Ownership since our separation from Cendant in July 2006. Mr. Hanning was the Chief Executive Officer of Cendant's Timeshare Resort Group from March 2005 until our separation from Cendant in July 2006. Mr. Hanning served as President and Chief Executive Officer of Fairfield Resorts, Inc. (which has been renamed Wyndham Vacation Resorts, Inc.) from April 2001, when Cendant acquired Fairfield, to March 2005 and as President and Chief Executive Officer of Trendwest Resorts, Inc. (which has been renamed Wyndham Resort Development Corporation) from August 2004 to March 2005. Mr. Hanning joined Fairfield in 1982 and held several key leadership positions with Fairfield, including Regional Vice President, Executive Vice President of Sales and Chief Operating Officer.
To view a complete list of Leadership visit: http://www.wyndhamworldwide.com/about-wyndham-worldwide/our-leadership
WYN Contact Info
Wyndham Worldwide Corporation
Seven Sylvan Way
Parsippany, NJ 07054
Phone: 973-753-6000
Website: http://www.wyndhamworldwide.com
facebook: http://www.facebook.com/WyndhamWorldwide
Margo C. Happer
Senior Vice President, Investor Relations
Phone: (973) 753-5500
E-mail: ir@wyn.com
WYN Recent Developments
Stock Information
http://www.wyndhamworldwide.com/investors/stock-information
Presentations
http://www.wyndhamworldwide.com/investors/presentations
SEC Filings
http://www.wyndhamworldwide.com/investors/earnings-financials
Competitors
http://finance.yahoo.com/q/co?s=WYN+Competitors
Industry
http://finance.yahoo.com/q/in?s=WYN+Industry
Headlines
http://www.wyndhamworldwide.com/investors/press-releases
Webcast & Events
http://www.wyndhamworldwide.com/investors/webcasts-events
Ownership
http://finance.yahoo.com/q/it?s=WYN+Insider+Transactions
WYN Products & Services
Wyndham Hotel Group
Wyndham Hotel Group is the world's largest and most diverse hotel company with approximately 7,200 hotels worldwide. With iconic brands and hotel choices in every category from upscale to economy, we offer not only the most lodging choices around the world but also exceptional customer service and great value.
Wyndham Rewards®, our guest loyalty program, offers attainable travel for the pragmatic traveler. The program is the largest in the lodging industry based on the number of participating hotels. Members earn valuable points for their stays, which may be redeemed for a variety of reward options, including airline travel, resort vacations, event tickets, gift certificates for leading retailers and restaurants and more.
Wyndham Exchange & Rentals
As the global leader in vacation exchange and the world's largest serviced vacation rentals business, Wyndham Exchange & Rentals helps to deliver dream vacations to leisure travelers, including our 3.8 million RCI subscribing members. We provide access for specified periods to approximately 97,000 vacation properties in nearly 100 countries, including vacation ownership condominiums, traditional hotel rooms, villas, cottages, bungalows, campgrounds, city apartments, second homes, fractional resorts, private residence clubs, condo hotels and yachts. We also provide products and services to our clients that help support the growth of their businesses and the leisure real estate industry around the world.
Wyndham Vacation Ownership
Wyndham Vacation Rentals offers one of the largest and most diverse collections of serviced vacation rental accommodations in the world. Providing inventory for specified periods to more than 90,000 vacation properties in over 500 unique destinations worldwide, we offer a complete range of vacation experiences from cottage/homes, villas and luxury homes, resorts, apartments/condos to boats, parks/lodges and camping accommodations. We also give approximately 51,000 independent vacation property owners the opportunity to rent their properties through our well-known vacation rental brands, including Hoseasons, cottages4you, Novasol®, Cuendet®, Landal GreenParks®, James Villa Holidays, Canvas Holidays, ResortQuest® and more.
Vacationers can spend a week or two living among the locals in a luxurious Italian Villa (Cuendet, Italian Country Cottages), explore England's vast network of canals and waterways - and maybe a few pubs – as the captain of their own narrowboat (Blakes, Hoseasons), see France from a camper's point of view by staying in a "super" tent, camper or lodge (Canvas Holidays), or ski the snow capped mountains of Park City, Utah (ResortQuest).
Wyndham Vacation Rentals offers an experience for every traveler and rental opportunities for every owner. For more information visithttp://www.wyndhamrentals.com
http://www.womenontheirway.com/
http://www.wyndhamworldwide.com/corporate-responsibility/wyndham-green
https://www.wyndhamrewards.com/trec/consumer/home.action
http://en.wikipedia.org/wiki/Wyndham_Worldwide
WYN Financial Reporting/Disclosure & Security Details
Wyndham Worldwide follows under these quidelines on the NYSE market tier.
Investigate more @ http://www.otcmarkets.com/stock/WYN/quote and http://finance.yahoo.com/q?s=WYN for more due diligence.
Share Structure
Market Cap: 6.12B
Shares Outstanding: 154,017,892 per last 10Q listed below
Authorized Shares: 600,000,000 per last 10Q listed below
Par Value: .01
http://finance.yahoo.com/q/ks?s=WYN+Key+Statistics
Shareholders
Shareholders of Record: 6,489
Transfer Agent(s)
Wells Fargo Shareowner Services
PO Box 64854
St. Paul, MN 55164-0854
(800) 504 8998
www.wellsfargo.com/shareownerservices
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
CIK: 0001361658
Fiscal Year End: Dec 31
OTC Market Tier: NYSE
Profile Data
SIC - Industry Classification: 7011
Sector: Services
Industry: Lodging
Business Status Development Stage Company:
Incorporated In: DE, USA
Employees: 26,400
WYN OTC Disclosure last 10Q reported Sept 30, 2011 period ending Oct 26, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8203788
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, WYN website
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Wyndham Worldwide Corp. ~ WYN ~Due Diligence~~~
Wyndham Worldwide is one of the world's largest hospitality companies across six continents. We offer individual consumers and business customers a broad array of hospitality products and services as well as various accommodation alternatives and price ranges through our premier portfolio of world-renowned brands.
The Company operates in the following business segments:
*Lodging —franchises hotels in the upper upscale, upscale, upper midscale, midscale, economy and extended stay segments of the lodging industry and provides hotel management services for full-service hotels globally.
*Vacation Exchange and Rentals —provides vacation exchange services and products to owners of intervals of vacation ownership interests (“VOIs”) and markets vacation rental properties primarily on behalf of independent owners.
*Vacation Ownership —develops, markets and sells VOIs to individual consumers, provides consumer financing in connection with the sale of VOIs and provides property management services at resorts.
Wyndham Vacation Rentals, the world's largest professionally managed vacation rentals business, is part of Wyndham Exchange & Rentals and the Wyndham Worldwide family of brands (NYSE: WYN). Backed by the world's largest hospitality company, Wyndham Vacation Rentals provides access to more than 94,000 vacation rental properties in over 500 unique destinations worldwide. Specializing in the managed vacation rental segment, Wyndham works closely with property owners to ensure all rentals meet its standards for customer service, quality and comfort. With a diverse and celebrated collection of more than 25 rental brands including Canvas Holidays, Hoseasons, James Villa Holidays, Landal GreenParks(R), Novasol(R), ResortQuest(R) and The Resort Company, Wyndham Vacation Rentals delivers distinct vacation experiences, ranging from beachfront condos, private homes, villas, castles and houseboats, with many properties offering kitchens, washers and dryers, maid service, spa and fitness centers, and golf courses. For additional information visit our media center at http://www.wyndhamworldwide.comor http://www.wyndhamrentals.com. Wyndham Vacation Rentals also can be found on Facebook at http://www.facebook.com/WyndhamWorldwide
http://youtu.be/0O3w09UWrRs
Key Company Management
Stephen P. Holmes
Chairman and Chief Executive Officer
Stephen P. Holmes has served as the Chairman of our Board of Directors and as our Chief Executive Officer since our listing on the New York Stock Exchange in July 2006. Prior to the creation of Wyndham Worldwide, Mr. Holmes was Vice Chairman and Director of Cendant and CEO of it's Travel Content Division since December 1997. Mr. Holmes was Vice Chairman and director of HFS Incorporated, from June 1994 until December 1997. From July 1990 through September 1996, Mr. Holmes served as Executive Vice President, Treasurer and Chief Financial Officer of HFS. Prior to the formation of HFS, Mr. Holmes was a managing director of The Blackstone Group and began his career as a Certified Public Accountant with Deloitte.
Geoff Ballotti
President and Chief Executive Officer
Wyndham Exchange & Rentals
Geoff Ballotti has served as president and chief executive officer, Wyndham Exchange & Rentals, since March 2008. In this role, Ballotti oversees more than 8,000 associates working in 72 offices in 33 countries. As president and CEO, he manages Wyndham Vacation Rentals, a diverse and celebrated collection of more than 25 vacation rentals brands from around the world, and RCI, the global leader in vacation exchange with a network of more than 4,000 affiliated resorts around the world and more than 3.7 million members. Prior to joining Wyndham Worldwide, Ballotti was president of the North America division of Starwood Hotels and Resorts. Geoff also brings international and global experience to Wyndham Exchange & Rentals, having led operations for Starwood in Europe. He speaks both French and Italian.
Eric A. Danziger
President and Chief Executive Officer
Wyndham Hotel Group
Eric A. Danziger has served as President and Chief Executive Officer of Wyndham Hotel Group since December 2008. Mr. Danziger has more than 30 years of hotel industry experience, starting as a bellman at the Fairmont Hotel in San Francisco and growing into progressively senior roles in hotel operations, general management and regional operations. His most recent hospitality experience includes serving as President and Chief Operating Officer of Carlson Hotels Worldwide, President and CEO of Starwood Hotels and Resorts Worldwide, and President of Wyndham Hotels and Resorts. Prior to joining Wyndham Worldwide, Danziger was CEO of WhiteFence, an online one–stop comparison shopping and transaction site for home services, and before that, president and CEO of ZipRealty, a national, full–service real estate brokerage.
Franz S. Hanning
President and Chief Executive Officer
Wyndham Vacation Ownership
Franz S. Hanning has served as President and Chief Executive Officer, Wyndham Vacation Ownership since our separation from Cendant in July 2006. Mr. Hanning was the Chief Executive Officer of Cendant's Timeshare Resort Group from March 2005 until our separation from Cendant in July 2006. Mr. Hanning served as President and Chief Executive Officer of Fairfield Resorts, Inc. (which has been renamed Wyndham Vacation Resorts, Inc.) from April 2001, when Cendant acquired Fairfield, to March 2005 and as President and Chief Executive Officer of Trendwest Resorts, Inc. (which has been renamed Wyndham Resort Development Corporation) from August 2004 to March 2005. Mr. Hanning joined Fairfield in 1982 and held several key leadership positions with Fairfield, including Regional Vice President, Executive Vice President of Sales and Chief Operating Officer.
To view a complete list of Leadership visit: http://www.wyndhamworldwide.com/about-wyndham-worldwide/our-leadership
WYN Contact Info
Wyndham Worldwide Corporation
Seven Sylvan Way
Parsippany, NJ 07054
Phone: 973-753-6000
Website: http://www.wyndhamworldwide.com
facebook: http://www.facebook.com/WyndhamWorldwide
Margo C. Happer
Senior Vice President, Investor Relations
Phone: (973) 753-5500
E-mail: ir@wyn.com
WYN Recent Developments
Stock Information
http://www.wyndhamworldwide.com/investors/stock-information
Presentations
http://www.wyndhamworldwide.com/investors/presentations
SEC Filings
http://www.wyndhamworldwide.com/investors/earnings-financials
Competitors
http://finance.yahoo.com/q/co?s=WYN+Competitors
Industry
http://finance.yahoo.com/q/in?s=WYN+Industry
Headlines
http://www.wyndhamworldwide.com/investors/press-releases
Webcast & Events
http://www.wyndhamworldwide.com/investors/webcasts-events
Ownership
http://finance.yahoo.com/q/it?s=WYN+Insider+Transactions
WYN Products & Services
Wyndham Hotel Group
Wyndham Hotel Group is the world's largest and most diverse hotel company with approximately 7,200 hotels worldwide. With iconic brands and hotel choices in every category from upscale to economy, we offer not only the most lodging choices around the world but also exceptional customer service and great value.
Wyndham Rewards®, our guest loyalty program, offers attainable travel for the pragmatic traveler. The program is the largest in the lodging industry based on the number of participating hotels. Members earn valuable points for their stays, which may be redeemed for a variety of reward options, including airline travel, resort vacations, event tickets, gift certificates for leading retailers and restaurants and more.
Wyndham Exchange & Rentals
As the global leader in vacation exchange and the world's largest serviced vacation rentals business, Wyndham Exchange & Rentals helps to deliver dream vacations to leisure travelers, including our 3.8 million RCI subscribing members. We provide access for specified periods to approximately 97,000 vacation properties in nearly 100 countries, including vacation ownership condominiums, traditional hotel rooms, villas, cottages, bungalows, campgrounds, city apartments, second homes, fractional resorts, private residence clubs, condo hotels and yachts. We also provide products and services to our clients that help support the growth of their businesses and the leisure real estate industry around the world.
Wyndham Vacation Ownership
Wyndham Vacation Rentals offers one of the largest and most diverse collections of serviced vacation rental accommodations in the world. Providing inventory for specified periods to more than 90,000 vacation properties in over 500 unique destinations worldwide, we offer a complete range of vacation experiences from cottage/homes, villas and luxury homes, resorts, apartments/condos to boats, parks/lodges and camping accommodations. We also give approximately 51,000 independent vacation property owners the opportunity to rent their properties through our well-known vacation rental brands, including Hoseasons, cottages4you, Novasol®, Cuendet®, Landal GreenParks®, James Villa Holidays, Canvas Holidays, ResortQuest® and more.
Vacationers can spend a week or two living among the locals in a luxurious Italian Villa (Cuendet, Italian Country Cottages), explore England's vast network of canals and waterways - and maybe a few pubs – as the captain of their own narrowboat (Blakes, Hoseasons), see France from a camper's point of view by staying in a "super" tent, camper or lodge (Canvas Holidays), or ski the snow capped mountains of Park City, Utah (ResortQuest).
Wyndham Vacation Rentals offers an experience for every traveler and rental opportunities for every owner. For more information visithttp://www.wyndhamrentals.com
http://www.womenontheirway.com/
http://www.wyndhamworldwide.com/corporate-responsibility/wyndham-green
https://www.wyndhamrewards.com/trec/consumer/home.action
http://en.wikipedia.org/wiki/Wyndham_Worldwide
WYN Financial Reporting/Disclosure & Security Details
Wyndham Worldwide follows under these quidelines on the NYSE market tier.
Investigate more @ http://www.otcmarkets.com/stock/WYN/quote and http://finance.yahoo.com/q?s=WYN for more due diligence.
Share Structure
Market Cap: 6.12B
Shares Outstanding: 154,017,892 per last 10Q listed below
Authorized Shares: 600,000,000 per last 10Q listed below
Par Value: .01
http://finance.yahoo.com/q/ks?s=WYN+Key+Statistics
Shareholders
Shareholders of Record: 6,489
Transfer Agent(s)
Wells Fargo Shareowner Services
PO Box 64854
St. Paul, MN 55164-0854
(800) 504 8998
www.wellsfargo.com/shareownerservices
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
CIK: 0001361658
Fiscal Year End: Dec 31
OTC Market Tier: NYSE
Profile Data
SIC - Industry Classification: 7011
Sector: Services
Industry: Lodging
Business Status Development Stage Company:
Incorporated In: DE, USA
Employees: 26,400
WYN OTC Disclosure last 10Q reported Sept 30, 2011 period ending Oct 26, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8203788
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, WYN website
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Thursday, January 19, 2012
Can I gain 100% in Stock Trading?
I am going to talk about positive profit growth today. I have said many times, determine what kind of trader you are and stick to your plan. First off I am going to say it again... Do YOUR Due Diligence and make sure a stock has the potential to get the profit percentage you want. Dig deep into the company and see what new's they have had and look to see what they have coming up the pipeline. Financials, acquisitions, etc. Are they at the top of their high's or low's? What do the indicators look like? Remember I watch the 50 day moving averages. You want the 50 day below the candles. I am going to use MGM as a chart example. They have been on a holy terror lately. The MACD's look great. By definition MACD:
Look where the 50 day moving average is. It is being supported great. MGM has great volume which is consistent on a daily basis. I also watch the 200 moving day average. It will show you the overall health of a stock. A stock trading below the 200 M/A is generally considered an unhealthy stock. Many traders will calculate this M/A as a reversal in the stock. Some traders like to buy a stock when the 50 M/A and 200 M/A cross each other. See where MGM crossed over last August and has stayed below this crossover? I am watching the 50 M/A to see if she continues to rise. If not, I will watch for a reversal. This is only my opinion and not to be construed as a buying signal. I am only saying what I am watching for.
I also watch the RSI. You want it to be high, which she is. I watch accumulation and distribution. It is a money flow indicator. MGM is still turned up. I like that. So my point is, there are tons of indicators many traders follow. If you are just starting out trading, basic indicators should be learned. I will continue to give lessons on how indicators can help in making profitable decisions. They don't always work, but ALWAYS be aware!
Ok, here's the meat of my subject today... If you want 100% profit in a stock, determine if the stock has the potential over more than one day of trading. Can you do it over the course of 5 days? 20% x 5 =100%. The stock market seems to come in folds of 20%'s. Even the Market Maker's want 20% on every trade. Watch and see as you learn. I will also elaborate on this subject soon as well. Until tomorrow, Happy Trading:)
Here is your free stock trading site of the day for Due Diligence: http://www.ddmachine.com/
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The MACD Line is the 12-day Exponential Moving Average (EMA) less the 26-day EMA. Closing prices are used for these moving averages. A 9-day EMA of the MACD Line is plotted with the indicator to act as a signal line and identify turns. The MACD Histogram represents the difference between MACD and its 9-day EMA, the Signal line. The histogram is positive when the MACD Line is above its Signal line and negative when the MACD Line is below its Signal line.
Look where the 50 day moving average is. It is being supported great. MGM has great volume which is consistent on a daily basis. I also watch the 200 moving day average. It will show you the overall health of a stock. A stock trading below the 200 M/A is generally considered an unhealthy stock. Many traders will calculate this M/A as a reversal in the stock. Some traders like to buy a stock when the 50 M/A and 200 M/A cross each other. See where MGM crossed over last August and has stayed below this crossover? I am watching the 50 M/A to see if she continues to rise. If not, I will watch for a reversal. This is only my opinion and not to be construed as a buying signal. I am only saying what I am watching for.
I also watch the RSI. You want it to be high, which she is. I watch accumulation and distribution. It is a money flow indicator. MGM is still turned up. I like that. So my point is, there are tons of indicators many traders follow. If you are just starting out trading, basic indicators should be learned. I will continue to give lessons on how indicators can help in making profitable decisions. They don't always work, but ALWAYS be aware!
Ok, here's the meat of my subject today... If you want 100% profit in a stock, determine if the stock has the potential over more than one day of trading. Can you do it over the course of 5 days? 20% x 5 =100%. The stock market seems to come in folds of 20%'s. Even the Market Maker's want 20% on every trade. Watch and see as you learn. I will also elaborate on this subject soon as well. Until tomorrow, Happy Trading:)
Here is your free stock trading site of the day for Due Diligence: http://www.ddmachine.com/
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Wednesday, January 18, 2012
6 Minutes of fame and then.... Flameout
Anyone get caught in the Gap and Trap that Stockgoodies/Sizzling Stock Picks ran yesterday? LYJN is the ticker and wow what a dog. Its a stop sign pk stock that is NOT current in its SEC filings and contrary to the goodies crews epiphany last week that they would not announce picks early to prevent gap ups, it was announced the weekend before and DID gap up. This is yet another play by a predator promoter trying to suck you in and make money off of you buying into their hype and stock manipulation.
At 9:27am there was a form T that came through pre-market. If you are not familiar with pennies, they do not normally trade pre-market unless there is a form T. To understand how a form T works; it is a buy or sell trade after the market closes end of day (EOD) and the market makers push it through. Clearly by the following image of the start of the day trading, someone tried to manipulate the stock price EOD on the 13th with $53 bucks. Can we say OOPs? Shame shame shame, you didn't push the buy button soon enough dumb ass to paint the chart.
Then also look at the selling going on at the bell. It gapped up 114% at the open with 200k in sells. Obviously someone did not wait to sell into the promotion. Another OOPS! Then the pain continued. The buy sell ratio continued a pattern all day long... SELL being the operative word. 6 minutes into the play she had 4MIL in volume but was only up 40% at this time. Dove 75%! At 9:40 someone purchased 400k in shares at .01. Someone obviously thought it was going to go back up and got caught in this gap and trap. Sad...
The RSI dropped below the 50% mark and never regained her buying power. At 9:43 this stock went flat and did nothing.
Even though it did 36MIL in volume yesterday, the buy sell ratio was selling.
Ok EOD, remember a few weeks ago I said the shorts will step in? Look at the form T of 10MIL at a lower stock price.
The stock campaign officially died at 10:53. Watch the 50 day moving average int he next couple days. I can almost guarantee it will drop below the 50 day M/A.
If you had done your due diligence you would have seen on OTC Markets that the company has a big warning sign on it and they have not filed quarterly reports since June of 2011.
Tomorrow we will look at the latest Goodie flameout and how they try to suck you back in when they fail to push a stock. Peace Im Outta HERE!!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
At 9:27am there was a form T that came through pre-market. If you are not familiar with pennies, they do not normally trade pre-market unless there is a form T. To understand how a form T works; it is a buy or sell trade after the market closes end of day (EOD) and the market makers push it through. Clearly by the following image of the start of the day trading, someone tried to manipulate the stock price EOD on the 13th with $53 bucks. Can we say OOPs? Shame shame shame, you didn't push the buy button soon enough dumb ass to paint the chart.
Then also look at the selling going on at the bell. It gapped up 114% at the open with 200k in sells. Obviously someone did not wait to sell into the promotion. Another OOPS! Then the pain continued. The buy sell ratio continued a pattern all day long... SELL being the operative word. 6 minutes into the play she had 4MIL in volume but was only up 40% at this time. Dove 75%! At 9:40 someone purchased 400k in shares at .01. Someone obviously thought it was going to go back up and got caught in this gap and trap. Sad...
The RSI dropped below the 50% mark and never regained her buying power. At 9:43 this stock went flat and did nothing.
Even though it did 36MIL in volume yesterday, the buy sell ratio was selling.
Ok EOD, remember a few weeks ago I said the shorts will step in? Look at the form T of 10MIL at a lower stock price.
If you had done your due diligence you would have seen on OTC Markets that the company has a big warning sign on it and they have not filed quarterly reports since June of 2011.
Tomorrow we will look at the latest Goodie flameout and how they try to suck you back in when they fail to push a stock. Peace Im Outta HERE!!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Monday, January 16, 2012
Happy MLK Day
Hey peeps, I took off the last few days to work on a business plan for a new business I will be starting by years end. After nearly 20 years of running my family's riding stable, I left in August of last year to pursue other things like this blog and some other business interests I have. My experience and expertise in the riding business though has continually called for me in the back of my head though. So, when a dear old friend mentioned he wanted to invest in a business with me I decided that the route I would take would be to open a new riding stable here in the Disney area using all of my knowledge I learned in so many years of being involved with the family's stable. I want to lay out the basic set up I used in making my business plan. First I started with the intent of the business plan. Next I stated the mission. Its important that you know that there is a difference between the intent of a business plan and the mission of the people involved in the business. The intent of my business plan is to set up a horseback riding stable in the Disney area and my mission is to provide a family oriented experience while taking care of our animals and preserving a piece of Americana. Now, the meat of the plan starts with the needs in setting up the business like land,equipment,buildings,inventory,staff,and obviously in my business horses. Next I listed out the initial costs of those things using an average of 3 resources for each to get a good broad idea of what the market was for those things I need. After that was done I listed out what my monthly costs will be based on my knowledge of former costs in the other business. My marketing plan is next and at first needs to be general as I believe that a true marketing plan is always being tweaked and retweaked as the business takes off. In my business we utilize websites,vacation guides and road signage as our basic entry level marketing tools. Projected income is next, and should be used to help keep my monthly costs in line so that obviously I dont have more going out than I have coming in. I often project my income lower, kind of as a built in expense checker so I dont build more than I can afford too quickly. Make sense? Lastly I list what I bring to the table personally as far as experience, drive etc etc. It is important to do this whether I am presenting the plan to investors or if I am doing it all on my own as it reaffirms my ability to do it. Business isnt always easy and its important I stay firm in my beliefs that I CAN do it. Now, if I am buying the land and building a business on it then that creates 2 different values as far as assets go. One is the business itself and the other the land. I think of them separately because, in the event that i build the business and want to sell it,I have the option of selling the business only and leasing the land to that business to keep a stream of income coming in. In the old days it was always figured that it takes 3 to 5 years for a new business to break even. Todays standards are 5 to 7 years. So, if i take in a gross amount of say $500,000 my first year, I am going to value my business at 2.5 to 3.5 million dollars just off of the cash flow that it produces. I then can add in my inventory and other equipment, horses etc into my total value of the business. The land would be worth whatever the current market levels are at but still worth something on its own. I hope I didnt get to deep on you on this and please feel free to ask any questions via the comments section. See ya soon!!!
Thursday, January 12, 2012
Promoterese 101
I received an interesting alert from a predator promoter group who thought they could just change their spots (name) and all the people they left holding bags would be none the smarter. After many months of telling the former mentioned promoter that not all of their plays should be paid,and that its good to profile stocks for free in order to give their followers a fighting chance at trusting them they balked. So low and behold the great white knight has come up with a free promotion. Many red flags are raised just by the deceptive wording of the alert :
This company is at ground zero of one of the biggest market stories of the decade. This is where the story gets juicy.
This company has positioned themselves in a much better Price per share area to attract investors and not just flippers. The current sector is already estimated at over $100 Billion, and with a projected 30 Million new customers coming into this sector in the next 10 years.
This company is showing us a strong Commitment to growth and seems to have the fundamentals that could keep them a major player in this industry for time to come!
My first problem with this deceptive alert is that it is a sub-penny stock. With the current SEC movement to rid the market of penny and sub penny stocks, a company actually positioning itself in a sub penny category is a farce and if in fact it is true then just downright ridiculous. Next is the creative wording the promoter uses... already estimated, and with a projected, seems to have the fundamentals that COULD. These are all deceptive twists intended to lure you into the hype of yet again another dog. Wanna know why its a free promo? Because the company has no money. It is actually most likely a tryout for the promoter to try to impress a third party who has a large position in it that they are good and are worthy of their business of deceiving you!! Plays like this also tend to be front loaded largely by the promoters cronies that they alert ahead of the play and those cronies will dump the stock as you buy in. Dont be duped by the Promoterese!!
This company is at ground zero of one of the biggest market stories of the decade. This is where the story gets juicy.
This company has positioned themselves in a much better Price per share area to attract investors and not just flippers. The current sector is already estimated at over $100 Billion, and with a projected 30 Million new customers coming into this sector in the next 10 years.
This company is showing us a strong Commitment to growth and seems to have the fundamentals that could keep them a major player in this industry for time to come!
My first problem with this deceptive alert is that it is a sub-penny stock. With the current SEC movement to rid the market of penny and sub penny stocks, a company actually positioning itself in a sub penny category is a farce and if in fact it is true then just downright ridiculous. Next is the creative wording the promoter uses... already estimated, and with a projected, seems to have the fundamentals that COULD. These are all deceptive twists intended to lure you into the hype of yet again another dog. Wanna know why its a free promo? Because the company has no money. It is actually most likely a tryout for the promoter to try to impress a third party who has a large position in it that they are good and are worthy of their business of deceiving you!! Plays like this also tend to be front loaded largely by the promoters cronies that they alert ahead of the play and those cronies will dump the stock as you buy in. Dont be duped by the Promoterese!!
Wednesday, January 11, 2012
I think its important that I show you what a good Due Diligence piece looks like so Ive put together a piece on a bio company so you can see the pertinent information that I look for when Im searching a company.
Curis, Inc.~ Nasdaq Bio~ CRIS due diligence
CRIS Company Overview & Description
Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com
CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf
CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf
CRIS Key Company Management
Daniel R. Passeri
President and Chief Executive Officer
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology.
Maurizio Voi, M.D.
Chief Medical and Chief Development Officer
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization.
Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy.
Michael P. Gray
Chief Operating and Chief Financial Officer
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College.
Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992.
Mark Noel
Vice President, Technology Management and Intellectual Property
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland.
CRIS Contact Info
Curis Inc. Corporate Headquarters
4 Maguire Road
Lexington, MA 02421
Tel: [617] 503-6500
Fax: [617] 503-6501
Website: http://www.curis.com
Email Alert Subscription: http://investors.curis.com/alerts.cfm?
Contact IR
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com
CRIS Recent Developments
SEC Filings
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings
Competitors
http://finance.yahoo.com/q/co?s=CRIS+Competitors
Industry
http://finance.yahoo.com/q/in?s=CRIS+Industry
Headlines
http://finance.yahoo.com/q/h?s=CRIS+Headlines
Current Corporate Collaborators
Collaborator Program Disease
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
http://www.curis.com/collaborations_detail.php?collaborationid=1
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.
http://www.curis.com/collaborations_detail.php?collaborationid=7
CRIS Products & Services
Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development.
Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications.
HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities.
Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner.
Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future.
CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development.
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing.
Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012.
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation).
In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.
Financial Reporting/Disclosure & Security Details
Shareholders tools: http://investors.curis.com/
CRIS follows under these quidelines on the Nasdaq market tier.
Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence.
Share Structure
Market Cap. (Mil) $336.19
Shares Out (Mil)76.58
Float (Mil)56.84
Share Related information provided by MorningStar, Inc.
Data as of Jan 9, 2012.
Mil=Millions
watch updates here: http://investors.curis.com/financials.cfm
Par Value: .01
Shareholders
Shareholders of Record: 76
Transfer Agent(s)
BNY Mellon Shareowner Services
P.O. Box 358015
85 Challenger Road
Pittsburgh, PA 15252-8015
Phone: 877.810.2248
TA Corporate Website: http://www.bnymellon.com/shareowner/isd
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210
CIK: 0001108205
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq
Profile Data
SIC - Industry Classification: CURIS, INC. - SIC # 2836
Sector: HealthCare
Industry: Biotechnology
Incorporated In: DE, USA
Year of Inc:
Employees: 32
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website
(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.)
Curis, Inc.~ Nasdaq Bio~ CRIS due diligence
CRIS Company Overview & Description
Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com
CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf
CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf
Daniel R. Passeri
President and Chief Executive Officer
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology.
Maurizio Voi, M.D.
Chief Medical and Chief Development Officer
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization.
Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy.
Michael P. Gray
Chief Operating and Chief Financial Officer
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College.
Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992.
Mark Noel
Vice President, Technology Management and Intellectual Property
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland.
Curis Inc. Corporate Headquarters
4 Maguire Road
Lexington, MA 02421
Tel: [617] 503-6500
Fax: [617] 503-6501
Website: http://www.curis.com
Email Alert Subscription: http://investors.curis.com/alerts.cfm?
Contact IR
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com
SEC Filings
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings
Competitors
http://finance.yahoo.com/q/co?s=CRIS+Competitors
Industry
http://finance.yahoo.com/q/in?s=CRIS+Industry
Headlines
http://finance.yahoo.com/q/h?s=CRIS+Headlines
Collaborator Program Disease
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
http://www.curis.com/collaborations_detail.php?collaborationid=1
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.
http://www.curis.com/collaborations_detail.php?collaborationid=7
Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development.
Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications.
HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities.
Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner.
Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future.
CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development.
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing.
Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012.
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation).
In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.
Shareholders tools: http://investors.curis.com/
CRIS follows under these quidelines on the Nasdaq market tier.
Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence.
Share Structure
Market Cap. (Mil) $336.19
Shares Out (Mil)76.58
Float (Mil)56.84
Share Related information provided by MorningStar, Inc.
Data as of Jan 9, 2012.
Mil=Millions
watch updates here: http://investors.curis.com/financials.cfm
Par Value: .01
Shareholders
Shareholders of Record: 76
Transfer Agent(s)
BNY Mellon Shareowner Services
P.O. Box 358015
85 Challenger Road
Pittsburgh, PA 15252-8015
Phone: 877.810.2248
TA Corporate Website: http://www.bnymellon.com/shareowner/isd
Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210
CIK: 0001108205
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq
Profile Data
SIC - Industry Classification: CURIS, INC. - SIC # 2836
Sector: HealthCare
Industry: Biotechnology
Incorporated In: DE, USA
Year of Inc:
Employees: 32
Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website
(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.)
As you can see this is NOT a penny or subpenny stock. I stay away from those as that is where most of the predator promoters and third parties who are looking for you to hold their bags are. Until tomorrow....
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Monday, January 9, 2012
Pump and Dump failure
Hey everyone. I had to take off a few days with a kidney infection but Im back as good as new. So did anyone catch the pump and dump failure of BRKM on thursday? After the big hype a certain flailing promoter put out on tuesday about preventing a big gap up by not announcing the ticker until after the bell opened, they postponed the ticker announcement until thursday and then proceeded to start pumping it on wednesday evening prior to thursdays open. The stock gapped up 17% then started a day long free fall that never recovered. Now if you got caught up in the hype and was left holding the bag, heres the negative due diligence that I uncovered with a little bit of digging:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8274281
OTC Disclosure last 10Q reported ___ period ending ___
On October 7, 2010 the Company, as Book Merge Technology, Inc, (BMT), entered into a plan of reorganization with a private company, Extreme Green Technologies Inc. (EGT). A reverse merger was effected on October 11, 2010, wherein BMT, (then a shell), was the surviving company and legal acquirer whereas EGT was the operating company. Accordingly, operations of the entity are reported as those of the original EGT, the operating company. BMT subsequently changed its name to Extreme Green Technologies, Inc., on August 12, 2011.
why hasnt it been updated anywhere???
a hole
weeeeeeeeeeeee
line 10 of 10Q
Common Stock
On September 1, 2011, 10,000,000 shares of common stock were issued in reducing the deferred investment loans by $10,000.
Shareholders of Record 235 a/o Nov 15, 2011
The promoter didnt even have the correct information about the share structure and float which I easily obtained by contacting the transfer agent. I highlighted one of my number one red flags in the comapany description which is...... Our mission is to..... which means we arent really doing anything but we want to..... The last promotion this company had one of the owners accounted for 50% of the stock sold during the promotion.... Can you say DILUTION? On a sinking ship, the first ones to jump off are the RATS. The float the promoter listed was a mere 10 million less than the actual float which is a pretty significant difference when trying to attract investors. What I am getting at again is.... dont trust every alert or shined up due diligence piece you see. Scrutinize it yourself and see the differences in the actual due diligence and what the promoter is putting out. Dont buy the smoke and mirrors! Until tomorrow have an awesome day!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
according to this map its a vacant lot???
http://www.loopnet.com/Property-Record/1560-N-Maple-Street-Corona-CA-92880/Yfb5Kim2g/Maps/
according to google the closest address to be found is 1260 and if you follow it down, 1557 is the last on the street
this site lists it as an automotive place: yellow pages
http://yellowpages.superpages.com/bp/Corona-CA/Automotive-Appearance-Specialists-L2189463242.htm
this one lists it as the content company
http://www.merchantcircle.com/business/The.Contents.Company.951-371-8106
Categories: Home & Garden | Home Repair & Improvement | Fire & Water Damage
Tags: building, restoration, preservation, corona,
http://start.cortera.com/company/research/k3m7qvr0s/r--j-leathercraft/
must be an office space but known the less
maybe frontloading?
Stock and Tier: BRKM QB per otc
does the company have a stockchart available?:
yes
http://www.nasdaq.com/
what is this stocks record volume:
avg daily volume: 108k
52 week high volume:
http://www.otcmarkets.com/stock/BRKM/insider-transactions
half of days volume was this guy selling
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7909547
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180462
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68483438&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67138322&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64259821&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180610&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180321&txt2find=steve|hayden
http://hot-news.posterous.com/?tag=entkpk
52 week low:
has this stock been promoted? http://newsletter.hotstocked.com/stocks
http://newsletter.hotstocked.com/stocks/view
http://newsletter.hotstocked.com/stocks/view/BRKM-BOOKMERGE-TECHNOLOGY
last promoted in june
was .22 in may when promoted and ran down ever since
BRKM turns trash into fuel for 840% revenue growth!Jun 22, 2011 08:10
http://www.otcmarkets.com
business description
BookMerge Technology is an alternative fuel and recycling company. Our mission is to provide a cost-effective, high-quality alternative diesel fuel, create "green" jobs, reduce the environmental impact of fossil fuels and diminish US reliance on foreign oil. On November 29, 2010 BookMerge aquired ExtremeGreen Technologies, Inc. dba Extreme Biodiesel to fulfill that mission. Extreme Biodiesel is a fully licensed and permitted Biodiesel producer operating in Corona, CA. Our facility has been an operating since January 2008, producing Biodiesel fuel (diesel fuel made from waste vegetable we collect), manufacturing personal biodiesel processors, and the recently added restaurant brown grease recycling service.
The correct float from the transfer agent is:
http://www.loopnet.com/Property-Record/1560-N-Maple-Street-Corona-CA-92880/Yfb5Kim2g/Maps/
according to google the closest address to be found is 1260 and if you follow it down, 1557 is the last on the street
this site lists it as an automotive place: yellow pages
http://yellowpages.superpages.com/bp/Corona-CA/Automotive-Appearance-Specialists-L2189463242.htm
this one lists it as the content company
http://www.merchantcircle.com/business/The.Contents.Company.951-371-8106
Categories: Home & Garden | Home Repair & Improvement | Fire & Water Damage
Tags: building, restoration, preservation, corona,
http://start.cortera.com/company/research/k3m7qvr0s/r--j-leathercraft/
must be an office space but known the less
maybe frontloading?
Stock and Tier: BRKM QB per otc
does the company have a stockchart available?:
yes
http://www.nasdaq.com/
what is this stocks record volume:
| 04/29/2011 | 0.1 | 0.22 | 0.09 | 0.15 | 2,228,041 |
avg daily volume: 108k
52 week high volume:
| 04/29/2011 | 0.1 | 0.22 | 0.09 | 0.15 | 2,228,041 |
| Apr 29, 2011 | HAYDEN STEVE Beneficial Owner (10%) | direct | Sell | 0.095 | 1,018,841 |
http://www.otcmarkets.com/stock/BRKM/insider-transactions
half of days volume was this guy selling
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7909547
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180462
Steve Hayden is involved in this, that means its not going to go good for the investor once he gets out. I notice BRKM has Extreme Biodiesel, a former part of Envirotek. That was a bad company then, and it is now. They are actually re releasing old ENTK press as new BRKM press.
june 2011
june 2011
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68483438&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67138322&txt2find=entk
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64259821&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180610&txt2find=steve|hayden
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64180321&txt2find=steve|hayden
http://hot-news.posterous.com/?tag=entkpk
52 week low:
| 12/12/2011 | 0.01 | 0.01 | 0.007 | 0.0099 | 144,000 |
has this stock been promoted? http://newsletter.hotstocked.com/stocks
http://newsletter.hotstocked.com/stocks/view
http://newsletter.hotstocked.com/stocks/view/BRKM-BOOKMERGE-TECHNOLOGY
last promoted in june
was .22 in may when promoted and ran down ever since
BRKM turns trash into fuel for 840% revenue growth!Jun 22, 2011 08:10
BRKM Announces 840% Increase in Revenue for Q4 2011, After 400% Revenue Jump Previously Announced for Q1 2011! Extreme Biodiesel is a wholly-owned Corona, California-based Bookmerge Technology, Inc subsidiary involved with the development, marketing, and commercialization of bulk bio-diesel fuel, personal biodiesel processors, and related products. Extreme Biodiesel currently operates primarily in the state of California, but provides ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$15,000 | 49,803 | |
Max Profit: 3.78 % | Gain at close: -0.67 % |
(YOU) Must read before 10PM - Doubting Me Could Cost Ya HugeJun 15, 2011 20:48Research Driven InvestorBy David Cohen 6/15/2011 Why RDI? David Cohen, Editor and Publisher of the Research Driven Investor, now ranked as one of the top five performing micro-cap investment newsletters in America from 2003 to 2009. David Cohen reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$40,000 | UNKNOWN | |
Max Profit: 7.14 % | Gain at close: 7.14 % |
BRKM Can It Triple - (Open Fast)Jun 15, 2011 16:07Research Driven InvestorBy David Cohen 6/15/2011 Why RDI? David Cohen, Editor and Publisher of the Research Driven Investor, now ranked as one of the top five performing micro-cap investment newsletters in America from 2003 to 2009. David Cohen reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$40,000 | 64,037 | |
Max Profit: 7.14 % | Gain at close: 7.14 % |
Past History Shows BRKM Has Explosive Potential!May 20, 2011 07:32 BookMerge Technology, Inc. - BRKM Past History Shows BRKM Has Explosive Potential! BRKM is an alternative fuel and recycling company whose mission is to provide a cost effective, high quality alternative diesel fuel, create Green Jobs, reduce the environmental impact of fossil fuels and diminish U.S. reliance on foreign oil. This mission statement has so much good stuff in it I don̢۪t ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$7,500 | 24,387 | |
Max Profit: 0.06 % | Gain at close: -6.19 % |
Past History Shows BRKM Has Explosive Potential!May 20, 2011 07:22 BookMerge Technology, Inc. - BRKM Past History Shows BRKM Has Explosive Potential! BRKM is an alternative fuel and recycling company whose mission is to provide a cost effective, high quality alternative diesel fuel, create Green Jobs, reduce the environmental impact of fossil fuels and diminish U.S. reliance on foreign oil. This mission statement has so much good stuff in it I don̢۪t ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
$7,500 | 24,387 | |
Max Profit: 0.06 % | Gain at close: -6.19 % |
Mybestpicksever - TRDX,BRKM,AEFI,SOLU,SOPV updateFeb 09, 2011 13:49Hello members, Here is our update for the 5 Power plays we suggested 3 days ago for your review, and as you can see we SMOKED IT AGAIN! All made money except BRKM the jury is still out on that one.. We believe in providing our members with WINNING penny picks. Congratulations to all of our subscribers who have received our free newsletter and have invested in our picks, get ready for yet another great play comming your way real soon ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % | |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % |
Mybestpicksever - BRKM our Biodiesel playFeb 07, 2011 08:43Hello members, The Green sector is Hot and we have found a company that is ready to emerge as a leader in an industry and location that is ready to explode!!!!!!!!!!!!!!! The biodiesel sector is heating up again, especially with current legislation extending tax credits and subsidizing costs of up to $1.00 a gallon. BookMerge Technology (BRKM) is an alternative fuel and recycling company. The company's ...read more
Promoter: | Paying Party: |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
Unknown compensation | UNKNOWN | |
Max Profit: 8.33 % | Gain at close: 0.00 % |
http://www.otcmarkets.com
- Website:http://www.extremebiodiesel.com
- Email: info@extremebiodiesel.com
business description
BookMerge Technology is an alternative fuel and recycling company. Our mission is to provide a cost-effective, high-quality alternative diesel fuel, create "green" jobs, reduce the environmental impact of fossil fuels and diminish US reliance on foreign oil. On November 29, 2010 BookMerge aquired ExtremeGreen Technologies, Inc. dba Extreme Biodiesel to fulfill that mission. Extreme Biodiesel is a fully licensed and permitted Biodiesel producer operating in Corona, CA. Our facility has been an operating since January 2008, producing Biodiesel fuel (diesel fuel made from waste vegetable we collect), manufacturing personal biodiesel processors, and the recently added restaurant brown grease recycling service.
23,373,500 per Lucy
BRKM Security Details
Share Structure
Market Value1 $2,513,247 a/o Jan 03, 2012 Shares Outstanding 114,238,500 a/o Sep 30, 2011 Float 13,373,000 a/o Dec 01, 2010 Authorized Shares 200,000,000 a/o Dec 01, 2010 Par Value 0.001
Shareholders
Shareholders of Record 102 a/o Oct 06, 2011
Corporate Actions
Ex. Date Record Date Pay Date Dividend (0.00) Feb 26, 2010 Feb 25, 2010 Feb 25, 2010
Security Notes
- Capital Change=shs increased by 7 for 1 split. Ex-date=02/26/2010. Rec date=02/25/2010. Pay date=02/25/2010.
Short Selling Data
Short Interest 0 (-100%)
Jul 29, 2011 Significant Failures to Deliver No
Transfer Agent(s)
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Filer Audited Financials Not Available Latest Report Not Available Regulatory Agency Not Available CIK 0001440280 Fiscal Year End 6/30 OTC Market Tier OTCQB
Profile Data
SIC - Industry Classification 3433 - Heating equipment, except electric Business Status Development Stage Company a/o Dec 01, 2010 Incorporated In: NV, USA Year of Inc. 2007 Employees 3 a/o Dec 01, 2010
Company Officers
Richard B. Carter President, CEO, CFO Joe Spadafore Corporate Secretary
Company Directors
Richard B. Carter Joe Spadafore
Company Notes
- Formerly=Bigwest Environmental Inc. until 2-2010
BRKM Security Details
Share Structure
| Market Value1 | $2,513,247 | a/o Jan 03, 2012 |
| Shares Outstanding | 114,238,500 | a/o Sep 30, 2011 |
| Float | 13,373,000 | a/o Dec 01, 2010 |
| Authorized Shares | 200,000,000 | a/o Dec 01, 2010 |
| Par Value | 0.001 |
Shareholders
| Shareholders of Record | 102 | a/o Oct 06, 2011 |
Corporate Actions
| Ex. Date | Record Date | Pay Date | |
| Dividend (0.00) | Feb 26, 2010 | Feb 25, 2010 | Feb 25, 2010 |
Security Notes
|
Short Selling Data
| Short Interest | 0 (-100%) Jul 29, 2011 |
| Significant Failures to Deliver | No |
Transfer Agent(s)
Financial Reporting/Disclosure
| Reporting Status | U.S. Reporting: SEC Filer |
| Audited Financials | Not Available |
| Latest Report | Not Available |
| Regulatory Agency | Not Available |
| CIK | 0001440280 |
| Fiscal Year End | 6/30 |
| OTC Market Tier | OTCQB |
Profile Data
| SIC - Industry Classification | 3433 - Heating equipment, except electric |
| Business Status | Development Stage Company a/o Dec 01, 2010 |
| Incorporated In: | NV, USA |
| Year of Inc. | 2007 |
| Employees | 3 a/o Dec 01, 2010 |
Company Officers
| Richard B. Carter | President, CEO, CFO |
| Joe Spadafore | Corporate Secretary |
Company Directors
| Richard B. Carter | |
| Joe Spadafore |
Company Notes
- Formerly=Bigwest Environmental Inc. until 2-2010
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8274281
The aggregate market value of the registrant’s $0.001 par value common equity held by non-affiliates of the registrant was $1,325,859; this is based upon the last trade of the common stock at $0.35 on October 18, 2010. The Registrant had outstanding 80,090,500 shares of Common Stock.
As of October 25, 2010 there were 80,090,500 common shares par value $0.001 issued and outstanding.
(horribly outdated)OTC Disclosure last 10Q reported ___ period ending ___
On October 7, 2010 the Company, as Book Merge Technology, Inc, (BMT), entered into a plan of reorganization with a private company, Extreme Green Technologies Inc. (EGT). A reverse merger was effected on October 11, 2010, wherein BMT, (then a shell), was the surviving company and legal acquirer whereas EGT was the operating company. Accordingly, operations of the entity are reported as those of the original EGT, the operating company. BMT subsequently changed its name to Extreme Green Technologies, Inc., on August 12, 2011.
why hasnt it been updated anywhere???
a hole
| Employees | 3 a/o Dec 01, 2010 |
weeeeeeeeeeeee
line 10 of 10Q
The Company has potentially dilutive securities outstanding as of September 30, 2011 in the form of convertible debt. However the conversion would be anti dilutive, since the Company is in a loss position, and was therefore not considered in the calculation of earnings per share.
The following is a reconciliation of the numerator and denominator of the basic and diluted earnings per share computations for the three months ended September 30, 2011 and 2010:
Capital Structure
Common Stock
On September 1, 2011, 10,000,000 shares of common stock were issued in reducing the deferred investment loans by $10,000.
As at September 30, 2011 the Company was authorized to issue 200,000,000 common shares, of which 114,238,500 were issued and outstanding at September 30, 2011 and 80,090,500 at September 30, 2010.
Shareholders of Record 235 a/o Nov 15, 2011
Before You Invest - Investigate! Always do your own due diligence[/b]
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.
Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.
Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, __ website
The promoter didnt even have the correct information about the share structure and float which I easily obtained by contacting the transfer agent. I highlighted one of my number one red flags in the comapany description which is...... Our mission is to..... which means we arent really doing anything but we want to..... The last promotion this company had one of the owners accounted for 50% of the stock sold during the promotion.... Can you say DILUTION? On a sinking ship, the first ones to jump off are the RATS. The float the promoter listed was a mere 10 million less than the actual float which is a pretty significant difference when trying to attract investors. What I am getting at again is.... dont trust every alert or shined up due diligence piece you see. Scrutinize it yourself and see the differences in the actual due diligence and what the promoter is putting out. Dont buy the smoke and mirrors! Until tomorrow have an awesome day!
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Subscribe to:
Comments (Atom)